Professor Amy Brodtmann is a clinician-researcher leading the Cognitive Health Initiative at the School of Translational Medicine, Monash University. Her research achievements are considerable: >$AUD40 million grant funding, continuous NHMRC funding since 2001; >225 peer-reviewed papers in high-ranking journals (e.g., The Lancet Neurology, Neurology, JAMA Neurology), >12,000 citations, H-index 51. She has made significant contributions to dementia treatment, care, and research in Australia and internationally. She works as a stroke and cognitive neurologist, running cognitive neurology services at the Royal Melbourne Hospital and Eastern Health, where she leads dementia trials units. Amy was the inaugural Chair of the Australian chapter of the Organization of Human Brain Mapping, first woman Honorary Medical Advisor for Dementia Australia, inaugural President of the Australasian Cognitive Neurology Association, and serves on the editorial boards for Neurology, Stroke and International Journal of Stroke. She is Chair of the International Stroke Genetics Consortium 2025-27 and International Science Board member for the Vascular Brain Health Institute in Bordeaux, France. She is the only non-US resident on the Science Committee of the largest neurology organisation in the world, the American Academy of Neurology (AAN). In 2025, she received the Mentor Award from the Organisation for Human Brain Mapping (>10,000 members) in recognition of her international leadership in training and mentoring the next-generation of clinician-researchers. Amy’s research focuses on identifying risk factors for and protective factors against late-life cognitive impairment and dementia, with a view to brain health promotion. Her vision is brain health for all Australians.